In agreement with this, rapamycin treatment during stage III (day 5–8) would significantly decrease the CD43+ population (Additional file 7: Figure S2e), indicating that insulin is likely to function through mTOCR1 to regulate the emergence of HSPCs from HE. The gene discussed is INS; the disease is hereditary elliptocytosis.